Mon-Sat: 8.00-10.30, Sun: 8.00-4.00
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is actually  a   biotech which has proved helpful diligently but unsuccessfully to develop an one off therapy, variously called Pro 140, leronlimab, and Vyrologix. In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in phrases of potential […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful diligently but unsuccessfully to develop an one off therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in phrases of potential indications.

CytoDyn's inventories of leronlimab are actually building up, whether they'll ever be being used is actually an open question.


While CYDY  happens to be dawdling, market opportunities for leronlimab as a combination treatment in the curing of multi-drug-resistant HIV are actually closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my last several shares. My first CytoDyn post, "CytoDyn: What To Do When It's Too Good to be able to Be True?", set out what follows prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan presented such an extremely marketing image in the Uptick Newswire job interview which I came away with an inadequate opinion of the business.

Irony of irony, my bad viewpoint of the company has grown steadily, though the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger yet still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc.... has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your treatment and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV- infected subjects. Today's payment of $3.5 million transfers ownership of the know-how and also connected intellectual property from Progenics to CytoDyn, and also roughly 25 million mg of bulk drug substance.... milestone payments after commencement of a stage III clinical trial ($1.5 million) and the very first new drug application approval ($five million), and even royalty payments of 5 percent of net sales upon commercialization.

Since that point in time, CytoDyn's leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to acquire a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous indications and multiple therapies, it has this individual treatments in addition to a "broad pipeline of indications" as it places it. I call certain pipelines, "pipedots." In CytoDyn's case it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.

Its opening banner on its site (below) shows an energetic organization with diverse interests albeit focused on leronlimab, several illness types, multiple publications in addition to multiple delivering presentations.

Can all of it be smoke cigarettes and mirrors? That is a question I have been asking myself from the very start of the interest of mine in this business. Judging with the multiples of thousands of diverse responses on listings accessible through Seeking Alpha's CytoDyn Summary page, I'm a lot from alone in this particular question.

CytoDyn is a classic battleground, or even some may say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *